Chronic neuropathies - Chronic inflammatory demyelinating neuropathy and its variants

Frontiers of Neurology and Neuroscience

Volumn 26, Issue , 2009, Pages 12-25

  Ramchandren, Sindhu ^a   Lewis, Richard A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS;

ANAPHYLAXIS; ASEPTIC MENINGITIS; ATAXIA; CEREBROSPINAL FLUID; CHILL; CLINICAL EVALUATION; DEMYELINATING NEUROPATHY; DEMYELINATION; DIABETES MELLITUS; DISTAL ACQUIRED DEMYELINATING SENSORY NEUROPATHY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ELECTROMYOGRAPHY; ELECTROPHYSIOLOGY; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; IMMUNE MEDIATED DEMYELINATING NEUROPATHY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LABORATORY TEST; LEWIS SUMNER SYNDROME; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR NEUROPATHY; NAUSEA; NERVE BIOPSY; NERVE CONDUCTION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NERVE; PLASMAPHERESIS; POEMS SYNDROME; POLYRADICULONEUROPATHY; PORPHYRIA; PRIORITY JOURNAL; REFLEX DISORDER; REVIEW; SENSITIVITY AND SPECIFICITY; TENDON REFLEX; THROMBOEMBOLISM; VASCULITIS; DEMYELINATING DISEASE; ELECTRODIAGNOSIS; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

DEMYELINATING DISEASES; ELECTRODIAGNOSIS; HUMANS; NEURAL CONDUCTION; PERIPHERAL NERVES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 67649710450     PISSN: 16604431     EISSN: 16622804     Source Type: Book Series    
DOI: 10.1159/000212313     Document Type: Review

References (92)

1. Hughes RAC: Epidemiology of peripheral neuropathy. Curr Opin Neurol 1995;8:335-338.
2. Monticelli ML, Beghi E: Chronic symmetric polyneuropathy in the elderly. A field screening investigation in two regions of Italy: background and methods of assessment. The Italian General Practitioner Study Group (IGPSG). Neuroepidemiology 1993;12:96-105.
3. Vileikyte L: Psychological aspects of diabetic peripheral neuropathy. Diabetes Rev 1999;7:387-394.
4. Padua L, Schenone A, Aprile I, Benedetti L, Caliandro P, Tonali P, Orazio EN, Italian NEUROPA Study Group: Quality of life and disability assessment in neuropathy: a multicentre study. J Peripher Nerv Syst 2005;10:3-10.
5. The DCCT Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-568.
6. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA: The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26: 1790-1795.
7. Leger JM: Diagnosis of chronic neuropathy. J Neurol 1999;246:156-161.
8. Hughes RAC: Chronic idiopathic demyelinating polyradiculoneuropathy; in Hughes RAC (ed): Guillain-Barré Syndrome. Heidelberg, Springer, 1990, pp 205-241.
9. England JD, Gronseth GS, Franklin G, et al: Distal symmetrical polyneuropathy: definition for clinical research. Muscle Nerve 2005;31:113-123.
10. Dyck PJ, Dyck JB, Grant A, Fealey RD: Ten steps in characterizing and diagnosing patients with peripheral neuropathy. Neurology 1996;47:10-17.
11. McLeod JG: Investigation of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1995;58:274-283.
12. England JD, Gronseth GS, Franklin G, Carter GT, et al: Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72:185-192.
13. England JD, Gronseth GS, Franklin G, Carter GT, et al: Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 2009;39:106-115.
14. Austin JH: Recurrent polyneuropathies and their corticosteroid treatment: with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone and prednisone. Brain 1958;81: 157-192.
15. Dyck PJ, Lais AC, Ohta M, et al: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975; 50:621-637.
16. Lunn MP, Manji H, Choudhary P P, et al: Chronic inflammatory demyelinating polyradiculoneuropa-thy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66:677-680.
17. McLeod JG, Pollard JD, Macaskill P, et al: Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-913.
18. Hughes R, Sanders E, Hall S, et al: Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol 1992;49:612-616.
19. Oh SJ, Kurokawa K, de Almeida DF, et al: Subacute inflammatory demyelinating polyneuropathy. Neurology 2003;61:1507-1512.
20. Mori K, Hattori N, Sugiura M, et al: Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 2002;58:979-982.
21. Lewis RA: Chronic inflammatory demyelinating polyneuropathy. Neurol Clin 2007;25:71-87.
22. Markowitz JA, Jeste SS, Kang PB: Child neurology: chronic inflammatory demyelinating polyradiculoneuropathy in children. Neurology 2008;71:e74-e78.
23. Burns TM, Dyck PJ, Darras BT, Jones HR: Chronic inflammatory demyelinating polyradiculoneuropathy; in Jones HR, Devivo DC, Darras BT (eds): Neuromuscular Disorders of Infancy, Childhood and Adolescence: A Clinician's Approach. Philadelphia, Butterworth Heinemann, 2003, pp 445-468.
24. Connolly AM: Chronic inflammatory demyelinating polyneuropathy in childhood. Pediatr Neurol 2001;24:177-182.
25. Rossignol E, D'Anjou G, Lapointe N, Haddad E, Vanasse M: Evolution and treatment of childhood chronic inflammatory polyneuropathy. Pediatr Neurol 2007;36:88-94.
26. Simmons Z, Wald JJ, Albers JW: Chronic inflammatory demyelinating polyradiculoneuropathy in children. 1. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 1997;20:1008-1015.
27. Kieseier BC, Dalakas MC, Hartung H-P: Inflammatory mechanisms in chronic inflammatory demyelinating neuropathy. Neurology 2002; 59(Suppl 6):S7-S12.
28. Rezania K, Gundogdu B, Soliven B: Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Front Biosci 2004;9:939-945.
29. Quattrini A, Previtali SC, Keiseier BC, et al: Autoimmunity in the peripheral nervous system. Crit Rev Neurobiol 2003;151:1-39.
30. Ryan MM, Grattan-Smith PK, Procopia PG, Morgan G, Ouvrier RA: Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul Disord 2000;10: 298-406.
31. Thaisetthawatkul P, Logigian EL, Herrman DN: Dispersion of distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology 2002; 59:1526-1532.
32. van den Bergh PYK, Pieret F: Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004; 29:565-574.
33. Rajabally YA, Jacob S, Hbahbih M: Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst 2005;10:282-292.
34. Prineas JW: Demyelination and remyelination in recurrent idiopathic polyneuropathy: an electron microscope study. Acta Neuropathol (Berl) 1971;18: 34-57.
35. Bosboom WM, van den Berg LH, Franssen H: Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy. Brain 2001;124:2427-2438.
36. Molenaar DS, Vermeulen M, de Haan RJ: Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1998;64:84-89.
37. Vallat JM, Tabaraud F, Magy L, et al: Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases. Muscle Nerve 2003;27:478-485.
38. Sumner AJ, Saida K, Saida T, et al: Acute conduction block associated with experimental antiserum-mediated demyelination of peripheral nerve. Ann Neurol 1982;11:469-477.
39. Lafontaine S, Rasminsky M, Sumner AJ: Conduction block in rat myelinated fibres following acute exposure to anti-galactocerebroside serum. J Physiol 1982;323:287-306.
40. Scherer SS, Arroyo EJ: Recent progress on the molecular organization of myelinated axons. J Peripher Nerv Syst 2002;7:1-12.
41. Arroyo EJ, Sirkowski EE, Chitale R, Scherer SS: Acute demyelination disrupts the molecular organization of peripheral nervous system nodes. J Comp Neurol 2004;479:424-434.
42. Saperstein DS, Katz JS, Amato AA, et al: The clinical spectrum of chronic acquired demyelinating polyneuropathy. Muscle Nerve 2001;24:311-324.
43. Barohn RJ, Kissel JT, Warmolts JR, et al: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989; 46:878-884.
44. Ad hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1991;41: 617-618.
45. Hughes R, Bensa S, Willison H, et al: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
46. Joint Task Force of the EFNS and PNS: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2005;10:220-228.
47. Koski CL, Baumgarten M, Magder LS, et al: Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2009;277:1-8.
48. Van Schaik IN, Winer JB, De Haan R, Vermeulen M: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;2:CD001797.
49. Mehndiratta MM, Hughes RA, Agarwal P: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;3:CD003906.
50. Mehndiratta MM, Hughes RA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002;1: CD002062.
51. van Doorn PA, Brand A, Strengers PF, et al: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo controlled, crossover study. Neurology 1990;40:209-212.
52. Vermeulen M, van Doorn PA, Brand A, et al: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
53. Hahn AF, Bolton CF, Zochodne D, et al: Intravenous immunoglobulin treatment (IVIg) in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind placebo-controlled cross-over study. Brain 1996;119:1067-1078.
54. Mendell JR, Barohn RJ, Freimer ML, et al: Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
55. Simmons Z, Wald JJ, Albers JW: Chronic inflammatory demyelinating polyradiculoneuropathy in children. 2. Long-term follow-up, with comparison to adults. Muscle Nerve 1997;20:1569-1575.
56. Vedanarayanan V V, Kandt RS, Lewis DV Jr, Delong GR: Chronic inflammatory demyelinating polyra-diculoneuropathy of childhood: treatment with high-dose intravenous immunoglobulin. Neurology 1991;41:828-830.
57. Hattori N, Ichimura M, Aoki S, et al: Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. J Neurol Sci 1998;154:66-71.
58. van Doorn PA, Dippel DWJ, van Burken MMG, et al: Long-term IV immunoglobulin treatment in CIDP. J Peripher Nerv Syst 2003;8(Suppl 1):70.
59. Dyck PJ, Litchy WJ, Kratz KM, et al: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
60. Dyck PJ, Daube J, O'Brien, et al: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465.
61. Hahn AF, Bolton CF, Pillay N, et al: Plasma exchange therapy in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind, sham-controlled cross-over study. Brain 1996;119:1055-1066.
62. Korinthenberg R: Chronic inflammatory demyelinating polyradiculoneuropathy in children and their response to treatment. Neuropediatrics 1999; 30:190-196.
63. Saperstein DS, Katz JS, Amato AA, et al: Clinical spectrum of chronic acquired demyelinating polyneuropathy. Muscle Nerve 2001;24:311-324.
64. Gladstone DE, Prestrud AA, Brannagan TH: High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005;10:11-16.
65. Pavesi G, Cattaneo L, Marbini A, et al: Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002; 249:777-779.
66. Meriggioli MN, Rowin J: Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve 2000;23:433-435.
67. Lisak RP: Type I interferons and chronic inflammatory demyelinating polyneuropathy: treatment or cause? Muscle Nerve 2000;23:307-309.
68. Chin RL, Sherman WH, Sander H W, et al: Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2003;210:19-21.
69. Richez C, Blanco P, Lagueny A, et al: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005;64:1468-1470.
70. Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004;4:CD003280.
71. Lewis R, Sumner A, Brown MJ, et al: Chronic multifocal demyelinative neuropathy: a unique disorder with persistent conduction block. Neurology 1982; 32:958-962.
72. Saperstein DS, Amato AA, Wolfe GI, et al: Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner Syndrome. Muscle Nerve 1999;22:560-566.
73. Van den Berg-Vos RM, Van den berg LH, Franssen H, et al: Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity? Neurology 2000;54:26-32.
74. Oh SJ, Claussen GC, Kim DS: Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 1997;2:362-369.
75. Verschueren A, Azulay J P, Attarian S, et al: Lewis-Sumner syndrome and multifocal motor neuropathy. Muscle Nerve 2005;31:88-94.
76. Viala K, Renie L, Maisonobe T, et al: Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004;127:2010-2017.
77. Nikhar NJ, Lewis RA: Multifocal sensorimotor demyelinating neuropathy with persistent conduction block is distinct from multifocal motor neuropathy. Neurology 1998;50(Suppl):A206.
78. Rotta FT, Sussman AT, Bradley WG, et al: The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-139.
79. Oh SJ, Joy JJ, Kuruoglu R: 'Chronic sensory demyelinating neuropathy': chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992;55:677-680.
80. Sinnreich M, Klein CJ, Daube JR, et al: Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology 2004;63:1662-1669.
81. Katz JS, Saperstein DS, Gronseth G, et al: Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-620.
82. Feasby TE, Hahn AF, Koopman WJ, et al: Central lesions in chronic inflammatory demyelinating polyneuropathy: an MRI study. Neurology 1990;40: 476-478.
83. Sharma KR, Saadia D, Facca AG, et al: Chronic inflammatory demyelinating polyradiculoneuropathy associated with multiple sclerosis. J Clin Neuromuscul Dis 2008;9:385-396.
84. Zéphir H, Stojkovic T, Latour P, et al: Relapsing demyelinating disease affecting both the central and peripheral nervous systems. J Neurol Neurosurg Psychiatry 2008;79:1032-1039.
85. Jann S, Bramerio MA, Facchetti D, Sterzi R: Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long-term follow-up. J Neurol Neurosurg Psychiatry 2009;80:70-73.
86. Kalita J, Misra UK, Yadav RK: A comparative study of chronic inflammatory demyelinating polyradiculoneuropathy with and without diabetes mellitus. Eur J Neurol 2007;14:638-643.
87. Stewart JD, McKelvey R, Durcan L, Carpenter S, Karpati G: Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics. J Neurol Sci 1996;142(1-2):59-64.
88. Miyasaki H, Hasegawa O, Mori I, Matsumoto S, Arita T: Incidence of diabetic neuropathy which fulfils electrophysiologic criteria of CIDP. No To Shinkei 1999;51:415-418.
89. Tabaraud F, Lagrange E, Sindou P, Vandenberghe A, Levy N, Vallat JM: Demyelinating X-linked Charcot-Marie-Tooth disease: unusual electrophysiological findings. Muscle Nerve 1999;22:1442-1447.
90. Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB, et al: Coexistent hereditary and inflammatory neuropathy. Brain 2004;127:193-202.
91. Kelly JJ: Peripheral neuropathy: the importance of history and examination for correct diagnosis. Rev Neurol Dis 2005;2:150-153.
92. Benedetti L, Briani C, Grandis M, et al: Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007;12:102-107.